vs

Side-by-side financial comparison of Blink Charging Co. (BLNK) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $27.0M, roughly 1.2× Blink Charging Co.). On growth, Blink Charging Co. posted the faster year-over-year revenue change (-3.5% vs -23.8%). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -15.2%).

Blink Charging Co. is an American electric vehicle charging network operator headquartered in Bowie, Maryland. One of the top three EV charging networks in the United States, it has over 90,000 chargers globally in 25 countries.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BLNK vs DNA — Head-to-Head

Bigger by revenue
DNA
DNA
1.2× larger
DNA
$33.4M
$27.0M
BLNK
Growing faster (revenue YoY)
BLNK
BLNK
+20.3% gap
BLNK
-3.5%
-23.8%
DNA
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-15.2%
BLNK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLNK
BLNK
DNA
DNA
Revenue
$27.0M
$33.4M
Net Profit
$-30.6M
Gross Margin
15.8%
Operating Margin
-120.9%
-211.9%
Net Margin
-113.3%
Revenue YoY
-3.5%
-23.8%
Net Profit YoY
60.1%
EPS (diluted)
$-0.27
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLNK
BLNK
DNA
DNA
Q4 25
$27.0M
$33.4M
Q3 25
$27.1M
$38.8M
Q2 25
$28.7M
$49.6M
Q1 25
$20.7M
$48.3M
Q4 24
$28.0M
$43.8M
Q3 24
$25.2M
$89.0M
Q2 24
$33.3M
$56.2M
Q1 24
$37.6M
$37.9M
Net Profit
BLNK
BLNK
DNA
DNA
Q4 25
$-30.6M
Q3 25
$-86.0K
$-80.8M
Q2 25
$-32.0M
$-60.3M
Q1 25
$-20.7M
$-91.0M
Q4 24
$-76.7M
Q3 24
$-87.4M
$-56.4M
Q2 24
$-20.1M
$-217.2M
Q1 24
$-17.2M
$-165.9M
Gross Margin
BLNK
BLNK
DNA
DNA
Q4 25
15.8%
Q3 25
34.5%
Q2 25
16.8%
Q1 25
34.1%
Q4 24
15.7%
Q3 24
36.2%
Q2 24
32.2%
Q1 24
35.7%
Operating Margin
BLNK
BLNK
DNA
DNA
Q4 25
-120.9%
-211.9%
Q3 25
-1.7%
-231.8%
Q2 25
-103.0%
-132.1%
Q1 25
-103.2%
-184.1%
Q4 24
-274.2%
-236.3%
Q3 24
-350.3%
-62.0%
Q2 24
-62.1%
-396.7%
Q1 24
-46.5%
-469.1%
Net Margin
BLNK
BLNK
DNA
DNA
Q4 25
-113.3%
Q3 25
-0.3%
-207.9%
Q2 25
-111.3%
-121.6%
Q1 25
-99.9%
-188.2%
Q4 24
-273.7%
Q3 24
-347.0%
-63.3%
Q2 24
-60.3%
-386.4%
Q1 24
-45.7%
-437.3%
EPS (diluted)
BLNK
BLNK
DNA
DNA
Q4 25
$-0.27
$-1.41
Q3 25
$0.00
$-1.45
Q2 25
$-0.28
$-1.10
Q1 25
$-0.21
$-1.68
Q4 24
$-0.77
$-1.91
Q3 24
$-0.86
$-1.08
Q2 24
$-0.20
$-4.23
Q1 24
$-0.17
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLNK
BLNK
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$39.6M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$64.5M
$508.6M
Total Assets
$147.5M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLNK
BLNK
DNA
DNA
Q4 25
$39.6M
$422.6M
Q3 25
$23.1M
$495.5M
Q2 25
$25.3M
$559.4M
Q1 25
$42.0M
$325.3M
Q4 24
$55.4M
$561.6M
Q3 24
$64.6M
$616.2M
Q2 24
$73.9M
$730.4M
Q1 24
$93.5M
$840.4M
Stockholders' Equity
BLNK
BLNK
DNA
DNA
Q4 25
$64.5M
$508.6M
Q3 25
$90.8M
$559.8M
Q2 25
$70.8M
$613.0M
Q1 25
$102.6M
$647.4M
Q4 24
$115.5M
$716.1M
Q3 24
$194.5M
$797.9M
Q2 24
$278.4M
$833.1M
Q1 24
$296.7M
$987.3M
Total Assets
BLNK
BLNK
DNA
DNA
Q4 25
$147.5M
$1.1B
Q3 25
$171.3M
$1.2B
Q2 25
$168.4M
$1.2B
Q1 25
$199.1M
$1.3B
Q4 24
$215.0M
$1.4B
Q3 24
$303.0M
$1.5B
Q2 24
$380.3M
$1.6B
Q1 24
$404.5M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLNK
BLNK
DNA
DNA
Operating Cash FlowLast quarter
$683.0K
$-47.7M
Free Cash FlowOCF − Capex
$-47.7M
FCF MarginFCF / Revenue
-142.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLNK
BLNK
DNA
DNA
Q4 25
$683.0K
$-47.7M
Q3 25
$-3.0M
$-31.6M
Q2 25
$-16.7M
$-40.3M
Q1 25
$-11.9M
$-51.5M
Q4 24
$-13.5M
$-42.4M
Q3 24
$-9.1M
$-103.5M
Q2 24
$-4.3M
$-84.4M
Q1 24
$-21.5M
$-89.3M
Free Cash Flow
BLNK
BLNK
DNA
DNA
Q4 25
$-47.7M
Q3 25
$-4.9M
Q2 25
$-40.3M
Q1 25
$-14.2M
$-59.1M
Q4 24
$-14.4M
$-56.1M
Q3 24
$-10.1M
$-118.6M
Q2 24
$-10.0M
$-111.4M
Q1 24
$-24.3M
$-96.0M
FCF Margin
BLNK
BLNK
DNA
DNA
Q4 25
-142.8%
Q3 25
-18.0%
Q2 25
-81.2%
Q1 25
-68.6%
-122.4%
Q4 24
-51.5%
-128.0%
Q3 24
-40.1%
-133.2%
Q2 24
-30.1%
-198.2%
Q1 24
-64.7%
-252.9%
Capex Intensity
BLNK
BLNK
DNA
DNA
Q4 25
0.0%
Q3 25
6.9%
0.0%
Q2 25
0.1%
Q1 25
11.4%
15.8%
Q4 24
3.4%
31.3%
Q3 24
3.9%
16.9%
Q2 24
17.3%
48.1%
Q1 24
7.5%
17.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLNK
BLNK

Products$11.0M41%
Host Provider Fees$5.9M22%
Network$3.7M14%
Transferred Over Time$3.2M12%
Network Fees And Warranty Contracts$1.6M6%
Car Sharing Services$1.3M5%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons